HomeCompareIBAL vs ABBV

IBAL vs ABBV: Dividend Comparison 2026

IBAL yields 118.34% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IBAL wins by $7.92M in total portfolio value
10 years
IBAL
IBAL
● Live price
118.34%
Share price
$1.69
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.03M
Annual income
$3,014,923.49
Full IBAL calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — IBAL vs ABBV

📍 IBAL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIBALABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IBAL + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IBAL pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IBAL
Annual income on $10K today (after 15% tax)
$10,059.17/yr
After 10yr DRIP, annual income (after tax)
$2,562,684.97/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, IBAL beats the other by $2,541,628.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IBAL + ABBV for your $10,000?

IBAL: 50%ABBV: 50%
100% ABBV50/50100% IBAL
Portfolio after 10yr
$4.06M
Annual income
$1,519,847.63/yr
Blended yield
37.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IBAL
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IBAL buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIBALABBV
Forward yield118.34%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8.03M$102.3K
Annual income after 10y$3,014,923.49$24,771.77
Total dividends collected$7.29M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IBAL vs ABBV ($10,000, DRIP)

YearIBAL PortfolioIBAL Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$22,534$11,834.32$11,550$430.00+$11.0KIBAL
2$49,035$24,923.21$13,472$627.96+$35.6KIBAL
3$103,153$50,685.22$15,906$926.08+$87.2KIBAL
4$210,022$99,648.81$19,071$1,382.55+$191.0KIBAL
5$414,339$189,615.20$23,302$2,095.81+$391.0KIBAL
6$792,949$349,606.93$29,150$3,237.93+$763.8KIBAL
7$1,473,753$625,296.70$37,536$5,121.41+$1.44MIBAL
8$2,663,044$1,086,129.08$50,079$8,338.38+$2.61MIBAL
9$4,683,678$1,834,220.22$69,753$14,065.80+$4.61MIBAL
10$8,026,459$3,014,923.49$102,337$24,771.77+$7.92MIBAL

IBAL vs ABBV: Complete Analysis 2026

IBALStock

International Baler Corporation manufactures and sells baling equipment to compress various materials into bales for handling, shipping, disposal, storage, and recycling. The company offers general purpose horizontal and vertical balers for compaction of paper, corrugated boxes, and miscellaneous solid waste materials; and specialty balers, including scrap metal, drum crusher, textile, and double chamber balers that are used for textile materials, used clothing, aluminum cans, 55-gallon drums, and synthetic rubber. It also provides accessory equipment comprising conveyors, which carry waste from floor level to the top of horizontal balers; extended hoppers on such balers; rufflers, which break up material; electronic start/stop controls; hydraulic oil coolers and cleaners; fluffers; bale tying machines; and plastic bottle piercers, as well as service and repair work to general purpose and specialty balers. The company sells its products to waste producing retailers, manufacturing and fabricating plants, bulk material producers, solid waste recycling facilities, manufacturers of synthetic rubber and polymers, plastic and paper recycling facilities, textile and paper mills, power generating facilities, cotton gins, supermarkets and other retail outlets, and municipalities. In addition, the company markets its products through sales force, manufacturer's representatives, and dealers in the United States, Europe, the Far East, South America, and internationally. The company was formerly known as Waste Technology Corporation and changed its name to International Baler Corporation in March 2009. International Baler Corporation was founded in 1946 and is based in Jacksonville, Florida. International Baler Corporation is a subsidiary of Avis Industrial Corporation.

Full IBAL Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this IBAL vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IBAL vs SCHDIBAL vs JEPIIBAL vs OIBAL vs KOIBAL vs MAINIBAL vs JNJIBAL vs MRKIBAL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.